Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020
Amgen today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer taking place virtually from Jan. 28-31, 2021 . Phase 2 data from the CodeBreaK 100 clinical study, evaluating investigational sotorasib in patients with KRAS G12C -mutated advanced non-small cell lung cancer …
Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer taking place virtually from Jan. 28-31, 2021 .
Share this article
DRESDEN, Germany, Jan. 7, 2021 /PRNewswire/
GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to- treat cancers, today announced the acceptance of two presentations on clinical data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the 2021 EHA-EBMT 3rd European CAR T-Cell Meeting, being held from February 4-6.
So far, CAR-T cell therapy in AML has been impacted by the lack of antigens differentially expressed on malignant blasts. Targeting CD123, which is also expressed on hematopoietic progenitor cells, with conventional CAR-T products has led to promising response rates but also to long-lasting aplasias, with the frequent need for subsequent allogeneic hematopoietic cell transplantation.